MCID: ANL011
MIFTS: 33

Anal Canal Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Anal Canal Carcinoma

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 54 12 13 42 14
Carcinoma of Anal Canal 12 69
Anal Canal and Perianal Gland Carcinoma 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
anal canal carcinoma:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 105580
Disease Ontology 12 DOID:6126
MeSH 42 C563020
NCIt 47 C7489
SNOMED-CT 64 285310000
ICD10 33 C21.1
SNOMED-CT via HPO 65 263681008
UMLS 69 C0563211

Summaries for Anal Canal Carcinoma

Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to anal carcinoma in situ and charcot-marie-tooth disease type 2a, and has symptoms including anal canal squamous carcinoma An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma). The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver, prostate and testes, and related phenotype is neoplasm.

Description from OMIM: 105580

Related Diseases for Anal Canal Carcinoma

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma

Symptoms & Phenotypes for Anal Canal Carcinoma

Symptoms via clinical synopsis from OMIM:

54

Oncology:
anal canal squamous carcinoma


Clinical features from OMIM:

105580

Human phenotypes related to Anal Canal Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 32 HP:0006763

MGI Mouse Phenotypes related to Anal Canal Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDKN2A GLI1 NME1 NQO1

Drugs & Therapeutics for Anal Canal Carcinoma

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
4 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
5 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
6 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
7 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
8 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
10 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
11
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
12
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
13
Daratumumab Approved Phase 1, Phase 2 945721-28-8
14
nivolumab Approved Phase 1, Phase 2 946414-94-4
15
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
16
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
17
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
18 Antibodies Phase 2,Phase 1
19 Antibodies, Monoclonal Phase 2,Phase 1
20 Immunoglobulins Phase 2,Phase 1
21 Liver Extracts Phase 2
22 Albumin-Bound Paclitaxel Phase 2
23 Antimitotic Agents Phase 2
24 Antineoplastic Agents, Phytogenic Phase 2
25 taxane Phase 2
26 Tempol Investigational Phase 1 2226-96-2
27 Protective Agents Phase 1
28 Antioxidants Phase 1
29 Neuroprotective Agents Phase 1
30 Radiation-Protective Agents Phase 1
31
acetic acid Approved, Nutraceutical 64-19-7 176
32
Vitamin A Approved, Nutraceutical, Vet_approved 11103-57-4, 68-26-8 445354
33 Adjuvants, Immunologic
34
Retinol acetate 127-47-9 10245972
35 Retinol palmitate
36 Vaccines
37 retinol Nutraceutical

Interventional clinical trials:

(show all 28)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
2 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
3 Vectibix for the Treatment of Anal Cancer Unknown status NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
4 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
5 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
6 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
7 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
8 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
9 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
10 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
11 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Recruiting NCT03302858 Phase 2
12 Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Active, not recruiting NCT02314169 Phase 2
13 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
14 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Active, not recruiting NCT00754078 Phase 2
15 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Not yet recruiting NCT03233711 Phase 2
16 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Suspended NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
17 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2 Nimotuzumab
18 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
19 Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer Terminated NCT01324141 Phase 1 Tempol;5-Fluorouracil;Mitomycin-C
20 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871
21 A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia Completed NCT02189161
22 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 DCF regimen
23 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
24 Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer Recruiting NCT02379039
25 Assessment of the Predictive Value of the Acetic Acid Test in Surgery Condition for the Detection of Dysplastic Lesions in Patients With Anal Condylomatosis Recruiting NCT03126123
26 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Active, not recruiting NCT01325961
27 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Active, not recruiting NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
28 The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men Enrolling by invitation NCT02503111

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Genetic Tests for Anal Canal Carcinoma

Anatomical Context for Anal Canal Carcinoma

MalaCards organs/tissues related to Anal Canal Carcinoma:

39
Liver, Prostate, Testes, Endothelial, Skin

Publications for Anal Canal Carcinoma

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 67)
id Title Authors Year
1
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
2
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2016
3
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
4
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
5
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2015
6
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
7
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
8
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
9
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
10
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
11
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
12
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
13
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
14
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
15
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
16
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. ( 20472349 )
2011
17
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. ( 22331724 )
2011
18
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. ( 21772841 )
2011
19
Anal canal carcinoma treatment results: the experience of a single institution. ( 21403412 )
2011
20
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. ( 21775274 )
2011
21
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. ( 19399614 )
2010
22
Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site. ( 21160444 )
2010
23
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( 20492729 )
2010
24
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. ( 19695047 )
2009
25
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( 18490648 )
2008
26
Chemotherapy and radiotherapy for anal canal carcinoma. ( 18812528 )
2008
27
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). ( 18191265 )
2008
28
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. ( 18505075 )
2008
29
The aspects of angiogenesis in anal canal carcinomas compared with that in colorectal carcinomas. ( 18060184 )
2007
30
External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. ( 17988027 )
2007
31
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. ( 18005443 )
2007
32
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. ( 16631268 )
2006
33
Anal canal carcinoma with Pagetoid spread: report of a case. ( 16794808 )
2006
34
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. ( 15752894 )
2005
35
Epidermal growth factor receptor expression in anal canal carcinoma. ( 15923158 )
2005
36
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. ( 15890590 )
2005
37
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. ( 12788191 )
2003
38
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. ( 11395235 )
2001
39
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. ( 11398611 )
2001
40
Analysis of a follow-up program for anal canal carcinoma. ( 11484975 )
2001
41
Prognostic impact of CD31 antigen expression in anal canal carcinoma. ( 11677963 )
2001
42
Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. ( 11277325 )
2000
43
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? ( 10914829 )
2000
44
An unusual late radiotherapy-related complication requiring surgery in anal canal carcinoma. ( 10914830 )
2000
45
Patterns of recurrence in anal canal carcinoma. ( 10982516 )
2000
46
Correlation between nm23-H1 overexpression and clinicopathological variables in human anal canal carcinoma. ( 10523705 )
1999
47
Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma. ( 10374676 )
1999
48
Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. ( 10435803 )
1999
49
Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? ( 9559628 )
1998
50
Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases. ( 9778618 )
1998

Variations for Anal Canal Carcinoma

Expression for Anal Canal Carcinoma

Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for Anal Canal Carcinoma

GO Terms for Anal Canal Carcinoma

Sources for Anal Canal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....